The pharmaceutical industry stands at a critical juncture, balancing the rapid acceleration of novel therapeutic modalities with the imperative to maintain stringent quality standards. As the landscape of drug development shifts toward more complex, individualized, and technologically advanced products, the role of public standards in ensuring safety and efficacy has never been more vital. In recognition of this, the American Association of Pharmaceutical Scientists (AAPS) and the United States Pharmacopeia (USP) have announced a major expansion of their strategic partnership for the upcoming 2026 PharmSci 360 conference.
Scheduled to take place from October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, the conference will serve as the backdrop for a significantly heightened USP presence. While the two organizations have collaborated in previous years—notably with exhibit-hall sessions in 2025 and targeted discussions on excipient grades in 2023—the 2026 event marks a formal leap in scale: a two-and-a-half-day dedicated workshop embedded within the conference’s core.
Main Facts: A Landmark Expansion of Engagement
The centerpiece of this collaboration is the USP-led workshop, running from October 26 to 28 directly within the PharmSci 360 exhibit hall. This intensive educational program is designed to bridge the gap between theoretical research and practical regulatory compliance. The workshop will focus on several pillars of modern pharmaceutical manufacturing:
- Complex Generics: Addressing the unique regulatory and analytical hurdles in bringing intricate generic formulations to market.
- Excipient Quality: Deep-diving into the critical role of inactive ingredients in drug stability and performance.
- Inhalation Standards: Navigating the complex testing requirements for respiratory drug delivery systems.
- Novel Excipients: Exploring the regulatory pathways for innovative materials that do not yet have long-standing compendial monographs.
These sessions are specifically curated to elucidate the compendial standards published in the USP–NF (United States Pharmacopeia and the National Formulary). These standards are not merely suggestions; they represent the benchmarks that the U.S. Food and Drug Administration (FDA) can enforce under the Federal Food, Drug, and Cosmetic Act. By providing a forum for these standards to be discussed, interpreted, and challenged by industry experts, the USP aims to foster a more predictable and transparent development environment.
Beyond the workshop, the USP will maintain a prominent footprint at booth 2931, where they will host a special poster collection highlighting current research and technical challenges in standard-setting.
Chronology: The Evolution of a Strategic Partnership
The 2026 announcement is the culmination of a multi-year effort to integrate regulatory science more deeply into the AAPS meeting agenda.
- 2023: The relationship focused on specific, high-interest topics, such as the grading and categorization of excipients and raw materials. This initial success demonstrated that AAPS attendees—primarily scientists and engineers—craved more granular, practical information regarding how USP standards influence daily development workflows.
- 2025: The collaboration grew to include stage sessions within the exhibit hall, allowing for more fluid, less formal interactions between USP experts and the industry. This format proved successful in breaking down the "ivory tower" perception of standard-setting organizations.
- 2026 (Upcoming): The transition to a sustained, multi-day workshop signifies a shift from "awareness" to "education." By dedicating over 48 hours of content to these issues, the USP is positioning itself as a central hub for collaborative problem-solving rather than just a publisher of standards.
Supporting Data: Scientific Leadership at the Podium
While the workshop is the focal point of the partnership, USP staff will be deeply embedded throughout the broader PharmSci 360 scientific program. This year, the focus is on the role of the USP as a facilitator of the global scientific discourse.
The Monday agenda is particularly notable. Dr. Diane McCarthy, Vice President of Global Biologics at USP, will deliver a keynote session on the future of public standards for biologics. As biologics move away from traditional batch-processing toward more continuous and highly specific manufacturing, the industry is grappling with how to define "quality" in a meaningful, reproducible way. Dr. McCarthy’s address will be moderated by Dr. Allison Radwick, Senior Regulatory and Policy Communications Manager at USP.
The symposium will also feature a powerhouse panel tackling some of the most debated topics in current biopharma:
- Monoclonal Antibody Economics: Dr. Anurag Rathore (Indian Institute of Technology Delhi) will lead a critical examination of next-generation manufacturing platforms, asking the provocative question of whether it is possible to produce monoclonal antibodies at a cost of $10 per gram.
- Formulation Strategy: Dr. Tongzhou Liu (AbbVie) will provide insights into the complex decision-making process for commercial manufacturing formulation choices.
- Advanced Delivery Systems: Dr. Luis Brito (Moderna) will offer a look into the current state of lipid nanoparticle (LNP) technology, a cornerstone of the mRNA therapeutic revolution.
Additionally, Dr. Ravi Kiran Kaja, a Senior Principal Scientist at USP, will moderate two pivotal keynotes: one featuring Dr. Alan Watts (Catalent) on the scale-up challenges of Inbrija, and another with Dr. Shawn Zhang (digiM Solution) on the cutting-edge use of microstructure-based predictive development.
Official Responses: Aligning Missions for Public Health
The collaboration is built on the realization that neither regulators nor industry players can solve modern pharmaceutical challenges in isolation. Catherine Sheehan, Senior Director of Growth Programs for Excipients and Foods at USP, articulated the philosophy behind this expanded role in a recent statement:
"USP and AAPS are aligned in our shared mission to help industry and regulators address evolving challenges in pharmaceutical quality. This workshop will bring together a range of stakeholder perspectives to foster innovation, strengthen regulatory confidence, and ultimately help increase the availability of quality medicines for the patients who need them."
This sentiment underscores a broader trend in the industry: the move toward "regulatory science" as a discipline in its own right. By bringing the creators of standards and the users of those standards into the same room, the USP hopes to shorten the feedback loop, ensuring that standards evolve as quickly as the drugs they oversee.
Implications: The Future of Pharmaceutical Quality
The implications of this partnership for the pharmaceutical industry are significant. As drug development becomes increasingly decentralized and reliant on third-party supply chains, the ability to adhere to a common language of quality—the USP standard—becomes the single most important factor in preventing supply chain failures and clinical trial delays.
1. Reducing Regulatory Friction
For the attendees, the primary benefit is the potential for reduced regulatory friction. Misunderstandings regarding USP monograph requirements often lead to delayed FDA approvals. By providing direct access to the scientists behind these monographs, the workshop offers a unique "early-warning system" for researchers who are working on products that may not fit neatly into current standards.
2. Standardizing Innovation
One of the most complex areas in current development is the use of "novel excipients"—materials that have not been widely used in approved drug products. Currently, the lack of standardized testing for these materials creates a bottleneck. The upcoming workshop discussions could serve as a catalyst for new, consensus-driven standards that allow innovators to move more quickly without sacrificing safety.
3. A Holistic Approach to the Pipeline
The PharmSci 360 conference itself serves as a barometer for the state of the industry. With a program spanning the entire development lifecycle—from preclinical discovery and analytical characterization to bioanalytics and manufacturing scale-up—the USP’s involvement ensures that quality is woven into the narrative of every stage. This is a departure from the historical model, where quality control was often treated as an "end-of-pipe" activity performed only after the drug was developed.
Conclusion: New Orleans and Beyond
As the industry converges on New Orleans in October 2026, the collaboration between AAPS and USP will serve as a vital blueprint for future industry-standard body cooperation. By moving away from static presentations and toward interactive, multi-day workshops, the organizations are acknowledging that in a world of $10-per-gram antibodies and complex nanoparticle formulations, the definition of "quality" is a moving target.
Through this enhanced partnership, the USP is not only providing the rules of the road but is actively participating in the conversation about where the road should lead. For attendees, the 2026 PharmSci 360 conference offers more than just a networking opportunity; it provides a direct line to the regulatory standards that will define the success or failure of the next generation of life-saving medicines. Whether for a startup focusing on a niche novel excipient or a major pharma company scaling up a blockbuster biologic, the insights gained in New Orleans promise to be foundational to the future of the field.
About the Author
